strontium,5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide

Modify Date: 2024-04-05 15:28:06

strontium,5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Structure
strontium,5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide structure
Common Name strontium,5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
CAS Number 914613-86-8 Molecular Weight 776.43600
Density N/A Boiling Point N/A
Molecular Formula C34H36N6O6S2Sr Melting Point N/A
MSDS N/A Flash Point N/A

 Use of strontium,5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide


Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

 Names

Name strontium,5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
Synonym More Synonyms

  Biological Activity

Description Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].
Related Catalog
In Vitro Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) hemistrontium treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1]. Cell Viability Assay[1] Cell Line: MDA-MB-468 cells Concentration: 25 µM, 50 µM, 75 µM, 100 µM Incubation Time: 20 hours Result: Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.
In Vivo Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) hemistrontium treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2]. Animal Model: C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2] Dosage: 30 mg/kg, 300 mg/kg Administration: Oral gavage; daily; for 19 or 11 days Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.
References

[1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46.

[2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16.

[3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.

 Chemical & Physical Properties

Molecular Formula C34H36N6O6S2Sr
Molecular Weight 776.43600
Exact Mass 776.11900
PSA 186.82000
LogP 6.78900

 Synonyms

1H-Benzimidazole,5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-,strontium salt
(-)-5-Methoxy-2-((S)-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzimidazole strontium salt
Esomeprazole strontium anhydrous
1H-Benzimidazole,6-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-,strontium salt (2:1)
Fm0F67 anhydrous
UNII-SCC2RK476A
Top Suppliers:I want be here

No recommended suppliers.

Hot Compounds More...
Dichloromethane
CAS#:75-09-2
Polyacrylic acid
CAS#:9003-01-4
sodium carbonate
CAS#:497-19-8
Silicon dioxide
CAS#:7631-86-9
Triethanolamine
CAS#:102-71-6
Demeton
CAS#:126-75-0
Water
CAS#:7732-18-5
4-(4-Piperidinyl)morpholine dihydrochloride
CAS#:53617-35-9
Diclofenac sodium
CAS#:15307-79-6
Budesonide
CAS#:51372-29-3